Clinical Trial Update: Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating TG01 antigen-specific cancer immunotherapy with gemcitabine as adjuvant in patients with resected pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• TG01

Snippet

Sponsor: Targovax ASA | Conditions: Pancreatic Cancer, Resected | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-14